Review



transfection positive control expressing gfp  (Addgene inc)


Bioz Verified Symbol Addgene inc is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    Addgene inc transfection positive control expressing gfp
    mAb B: effects of LC/HC promoter strength on titer, cell density, and viability <t>post-transfection</t> (72 hpt), and model profiling. (A) Viability (%), (B) viable cell density (VCD; cells/mL), and (C) titer (mg/L) for all LC/HC combinations. Promoter levels: 5, 40, and 100 RPU for both LC and HC. Bars show mean ± SD (n = 2). Statistical analysis was based on one-way ANOVA with Tukey's HSD; different letters indicate p < 0.05. (D) Transfection efficiency (% <t>GFP+)</t> of a control plasmid (pMAX-GFP) quantified by flow cytometry. (E) JMP profiler for least-squares models of titer, VCD, and viability versus LC/HC promoter strength. Left: predicted means with 95% Cls. Right: composite desirability (0-1) balancing high titer with acceptable VCD and viability. Red dashed lines mark targets/constraints.
    Transfection Positive Control Expressing Gfp, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 18 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/transfection+control/pmc12827772-30-54-61?v=Addgene+inc
    Average 93 stars, based on 18 article reviews
    transfection positive control expressing gfp - by Bioz Stars, 2026-08
    93/100 stars

    Images

    1) Product Images from "High-throughput optimization of antibody production in CHO cells by tuning heavy- and light-chain promoter strength"

    Article Title: High-throughput optimization of antibody production in CHO cells by tuning heavy- and light-chain promoter strength

    Journal: Frontiers in Bioengineering and Biotechnology

    doi: 10.3389/fbioe.2025.1747473

    mAb B: effects of LC/HC promoter strength on titer, cell density, and viability post-transfection (72 hpt), and model profiling. (A) Viability (%), (B) viable cell density (VCD; cells/mL), and (C) titer (mg/L) for all LC/HC combinations. Promoter levels: 5, 40, and 100 RPU for both LC and HC. Bars show mean ± SD (n = 2). Statistical analysis was based on one-way ANOVA with Tukey's HSD; different letters indicate p < 0.05. (D) Transfection efficiency (% GFP+) of a control plasmid (pMAX-GFP) quantified by flow cytometry. (E) JMP profiler for least-squares models of titer, VCD, and viability versus LC/HC promoter strength. Left: predicted means with 95% Cls. Right: composite desirability (0-1) balancing high titer with acceptable VCD and viability. Red dashed lines mark targets/constraints.
    Figure Legend Snippet: mAb B: effects of LC/HC promoter strength on titer, cell density, and viability post-transfection (72 hpt), and model profiling. (A) Viability (%), (B) viable cell density (VCD; cells/mL), and (C) titer (mg/L) for all LC/HC combinations. Promoter levels: 5, 40, and 100 RPU for both LC and HC. Bars show mean ± SD (n = 2). Statistical analysis was based on one-way ANOVA with Tukey's HSD; different letters indicate p < 0.05. (D) Transfection efficiency (% GFP+) of a control plasmid (pMAX-GFP) quantified by flow cytometry. (E) JMP profiler for least-squares models of titer, VCD, and viability versus LC/HC promoter strength. Left: predicted means with 95% Cls. Right: composite desirability (0-1) balancing high titer with acceptable VCD and viability. Red dashed lines mark targets/constraints.

    Techniques Used: Transfection, Control, Plasmid Preparation, Flow Cytometry

    mAb C: effects of LC/HC promoter strength on titer, cell density, and viability post-transfection (72 hpt), and model profiling. (A) Viability (6), (B) viable cell density (VCD; cells/mL), and (C) titer (mg/L) for all LC/HC combinations. Promoter levels: 5, 40, and 100 RPU for both LC and HC. Bars show mean = SD (n = 2). Statistical analysis was based on one-way ANOVA with Tukey’s HSD; different letters indicate p < 0.05. (D) JMP profiler for least-squares models of titer, VCD, and viability versus LC/HC promoter strength. Left: predicted means with 95% Cls. Right: composite desirability (0-1) balancing high titer with acceptable VCD and viability. Red dashed lines mark targets/constraints.
    Figure Legend Snippet: mAb C: effects of LC/HC promoter strength on titer, cell density, and viability post-transfection (72 hpt), and model profiling. (A) Viability (6), (B) viable cell density (VCD; cells/mL), and (C) titer (mg/L) for all LC/HC combinations. Promoter levels: 5, 40, and 100 RPU for both LC and HC. Bars show mean = SD (n = 2). Statistical analysis was based on one-way ANOVA with Tukey’s HSD; different letters indicate p < 0.05. (D) JMP profiler for least-squares models of titer, VCD, and viability versus LC/HC promoter strength. Left: predicted means with 95% Cls. Right: composite desirability (0-1) balancing high titer with acceptable VCD and viability. Red dashed lines mark targets/constraints.

    Techniques Used: Transfection

    mAb E: effects of LC/HC promoter strength on titer, cell density, and viability post-transfection (72 hpt), and model profiling. (A) Viability (%), (B) viable cell density (VCD; cells/mL), and (C) titer (mg/L) for all LC/HC combinations. Promoter levels: 5, 40, and 100 RPU for both LC and HC. Bars show mean ± SD (n = 2). Statistical analysis was based on one-way ANOVA with Tukey’s HSD; different letters indicate p < 0.05. (D) JMP profiler for least- squares models of titer, VCD, and viability versus LC/HC promoter strength. Left: predicted means with 95% CIs. Right: composite desirability (0-1) balancing high titer with acceptable VCD and viability. Red dashed lines mark targets/constraints.
    Figure Legend Snippet: mAb E: effects of LC/HC promoter strength on titer, cell density, and viability post-transfection (72 hpt), and model profiling. (A) Viability (%), (B) viable cell density (VCD; cells/mL), and (C) titer (mg/L) for all LC/HC combinations. Promoter levels: 5, 40, and 100 RPU for both LC and HC. Bars show mean ± SD (n = 2). Statistical analysis was based on one-way ANOVA with Tukey’s HSD; different letters indicate p < 0.05. (D) JMP profiler for least- squares models of titer, VCD, and viability versus LC/HC promoter strength. Left: predicted means with 95% CIs. Right: composite desirability (0-1) balancing high titer with acceptable VCD and viability. Red dashed lines mark targets/constraints.

    Techniques Used: Transfection



    Similar Products

    tye 563 fluorescent labeled transfection control  (OriGene)
    95
    OriGene tye 563 fluorescent labeled transfection control
    Tye 563 Fluorescent Labeled Transfection Control, supplied by OriGene, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/transfection+control/pm41579862-1027-10-15?v=OriGene
    Average 95 stars, based on 1 article reviews
    tye 563 fluorescent labeled transfection control - by Bioz Stars, 2026-08
    95/100 stars
    		  Buy from Supplier
    transfection positive control expressing gfp  (Addgene inc)
    93
    Addgene inc transfection positive control expressing gfp
    mAb B: effects of LC/HC promoter strength on titer, cell density, and viability <t>post-transfection</t> (72 hpt), and model profiling. (A) Viability (%), (B) viable cell density (VCD; cells/mL), and (C) titer (mg/L) for all LC/HC combinations. Promoter levels: 5, 40, and 100 RPU for both LC and HC. Bars show mean ± SD (n = 2). Statistical analysis was based on one-way ANOVA with Tukey's HSD; different letters indicate p < 0.05. (D) Transfection efficiency (% <t>GFP+)</t> of a control plasmid (pMAX-GFP) quantified by flow cytometry. (E) JMP profiler for least-squares models of titer, VCD, and viability versus LC/HC promoter strength. Left: predicted means with 95% Cls. Right: composite desirability (0-1) balancing high titer with acceptable VCD and viability. Red dashed lines mark targets/constraints.
    Transfection Positive Control Expressing Gfp, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/transfection+control/pmc12827772-30-54-61?v=Addgene+inc
    Average 93 stars, based on 1 article reviews
    transfection positive control expressing gfp - by Bioz Stars, 2026-08
    93/100 stars
    		  Buy from Supplier
    negative control sirna  (OriGene)
    96
    OriGene negative control sirna
    mAb B: effects of LC/HC promoter strength on titer, cell density, and viability <t>post-transfection</t> (72 hpt), and model profiling. (A) Viability (%), (B) viable cell density (VCD; cells/mL), and (C) titer (mg/L) for all LC/HC combinations. Promoter levels: 5, 40, and 100 RPU for both LC and HC. Bars show mean ± SD (n = 2). Statistical analysis was based on one-way ANOVA with Tukey's HSD; different letters indicate p < 0.05. (D) Transfection efficiency (% <t>GFP+)</t> of a control plasmid (pMAX-GFP) quantified by flow cytometry. (E) JMP profiler for least-squares models of titer, VCD, and viability versus LC/HC promoter strength. Left: predicted means with 95% Cls. Right: composite desirability (0-1) balancing high titer with acceptable VCD and viability. Red dashed lines mark targets/constraints.
    Negative Control Sirna, supplied by OriGene, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/transfection+control/pm41482890-253-30-25?v=OriGene
    Average 96 stars, based on 1 article reviews
    negative control sirna - by Bioz Stars, 2026-08
    96/100 stars
    		  Buy from Supplier
    sirna transfection precursor mirnas  (TargetMol)
    93
    TargetMol sirna transfection precursor mirnas
    mAb B: effects of LC/HC promoter strength on titer, cell density, and viability <t>post-transfection</t> (72 hpt), and model profiling. (A) Viability (%), (B) viable cell density (VCD; cells/mL), and (C) titer (mg/L) for all LC/HC combinations. Promoter levels: 5, 40, and 100 RPU for both LC and HC. Bars show mean ± SD (n = 2). Statistical analysis was based on one-way ANOVA with Tukey's HSD; different letters indicate p < 0.05. (D) Transfection efficiency (% <t>GFP+)</t> of a control plasmid (pMAX-GFP) quantified by flow cytometry. (E) JMP profiler for least-squares models of titer, VCD, and viability versus LC/HC promoter strength. Left: predicted means with 95% Cls. Right: composite desirability (0-1) balancing high titer with acceptable VCD and viability. Red dashed lines mark targets/constraints.
    Sirna Transfection Precursor Mirnas, supplied by TargetMol, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/transfection+control/pm41326795-187-30-29?v=TargetMol
    Average 93 stars, based on 1 article reviews
    sirna transfection precursor mirnas - by Bioz Stars, 2026-08
    93/100 stars
    		  Buy from Supplier
    non targeting control sirna  (Santa Cruz Biotechnology)
    96
    Santa Cruz Biotechnology non targeting control sirna
    GLO1 knockdown downregulates PD-L1 and enhances CD8 + T cell function in vitro. A Representative RT-qPCR of GLO1 and PD-L1 expression in A375 and 786-O cells after transfection with control (si-NC) or GLO1-specific (si-GLO1) <t>siRNA.</t> GAPDH served as a loading control. B , C Quantification of mRNA B and PD-L1 C protein levels normalized to GAPDH ( n = 3, * p < 0.05, ** p < 0.01). D Representative flow cytometry plots showing the percentage of CD8 + T cells apoptosis after culture in conditioned medium from si-NC or si-GLO1 A375 cells. E , F Statistical summary of TNF-a ( E ) and IFN-γ production ( F ) in CD8 + T cells cultured in conditioned medium from si-NC or si-GLO1 treated A375 and 786-O cells ( n = 3, * p < 0.05, ** p < 0.01)
    Non Targeting Control Sirna, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/transfection+control/pmc12748458-110-10-13?v=Santa+Cruz+Biotechnology
    Average 96 stars, based on 1 article reviews
    non targeting control sirna - by Bioz Stars, 2026-08
    96/100 stars
    		  Buy from Supplier
    non targeting nt control  (Qiagen)
    99
    Qiagen non targeting nt control
    GLO1 knockdown downregulates PD-L1 and enhances CD8 + T cell function in vitro. A Representative RT-qPCR of GLO1 and PD-L1 expression in A375 and 786-O cells after transfection with control (si-NC) or GLO1-specific (si-GLO1) <t>siRNA.</t> GAPDH served as a loading control. B , C Quantification of mRNA B and PD-L1 C protein levels normalized to GAPDH ( n = 3, * p < 0.05, ** p < 0.01). D Representative flow cytometry plots showing the percentage of CD8 + T cells apoptosis after culture in conditioned medium from si-NC or si-GLO1 A375 cells. E , F Statistical summary of TNF-a ( E ) and IFN-γ production ( F ) in CD8 + T cells cultured in conditioned medium from si-NC or si-GLO1 treated A375 and 786-O cells ( n = 3, * p < 0.05, ** p < 0.01)
    Non Targeting Nt Control, supplied by Qiagen, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/transfection+control/pmc12767607-405-18-21?v=Qiagen
    Average 99 stars, based on 1 article reviews
    non targeting nt control - by Bioz Stars, 2026-08
    99/100 stars
    		  Buy from Supplier
    cy3 conjugated mirna transfection control  (Cell Signaling Technology Inc)
    93
    Cell Signaling Technology Inc cy3 conjugated mirna transfection control
    GLO1 knockdown downregulates PD-L1 and enhances CD8 + T cell function in vitro. A Representative RT-qPCR of GLO1 and PD-L1 expression in A375 and 786-O cells after transfection with control (si-NC) or GLO1-specific (si-GLO1) <t>siRNA.</t> GAPDH served as a loading control. B , C Quantification of mRNA B and PD-L1 C protein levels normalized to GAPDH ( n = 3, * p < 0.05, ** p < 0.01). D Representative flow cytometry plots showing the percentage of CD8 + T cells apoptosis after culture in conditioned medium from si-NC or si-GLO1 A375 cells. E , F Statistical summary of TNF-a ( E ) and IFN-γ production ( F ) in CD8 + T cells cultured in conditioned medium from si-NC or si-GLO1 treated A375 and 786-O cells ( n = 3, * p < 0.05, ** p < 0.01)
    Cy3 Conjugated Mirna Transfection Control, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/transfection+control/pm41308698-89-0-7?v=Cell+Signaling+Technology+Inc
    Average 93 stars, based on 1 article reviews
    cy3 conjugated mirna transfection control - by Bioz Stars, 2026-08
    93/100 stars
    		  Buy from Supplier
    si nc transfected cells  (MedChemExpress)
    95
    MedChemExpress si nc transfected cells
    GLO1 knockdown downregulates PD-L1 and enhances CD8 + T cell function in vitro. A Representative RT-qPCR of GLO1 and PD-L1 expression in A375 and 786-O cells after transfection with control (si-NC) or GLO1-specific (si-GLO1) <t>siRNA.</t> GAPDH served as a loading control. B , C Quantification of mRNA B and PD-L1 C protein levels normalized to GAPDH ( n = 3, * p < 0.05, ** p < 0.01). D Representative flow cytometry plots showing the percentage of CD8 + T cells apoptosis after culture in conditioned medium from si-NC or si-GLO1 A375 cells. E , F Statistical summary of TNF-a ( E ) and IFN-γ production ( F ) in CD8 + T cells cultured in conditioned medium from si-NC or si-GLO1 treated A375 and 786-O cells ( n = 3, * p < 0.05, ** p < 0.01)
    Si Nc Transfected Cells, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/transfection+control/pm41270811-73-15-30?v=MedChemExpress
    Average 95 stars, based on 1 article reviews
    si nc transfected cells - by Bioz Stars, 2026-08
    95/100 stars
    		  Buy from Supplier
    turbofectin 8 0 based transfection system  (OriGene)
    93
    OriGene turbofectin 8 0 based transfection system
    GLO1 knockdown downregulates PD-L1 and enhances CD8 + T cell function in vitro. A Representative RT-qPCR of GLO1 and PD-L1 expression in A375 and 786-O cells after transfection with control (si-NC) or GLO1-specific (si-GLO1) <t>siRNA.</t> GAPDH served as a loading control. B , C Quantification of mRNA B and PD-L1 C protein levels normalized to GAPDH ( n = 3, * p < 0.05, ** p < 0.01). D Representative flow cytometry plots showing the percentage of CD8 + T cells apoptosis after culture in conditioned medium from si-NC or si-GLO1 A375 cells. E , F Statistical summary of TNF-a ( E ) and IFN-γ production ( F ) in CD8 + T cells cultured in conditioned medium from si-NC or si-GLO1 treated A375 and 786-O cells ( n = 3, * p < 0.05, ** p < 0.01)
    Turbofectin 8 0 Based Transfection System, supplied by OriGene, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/transfection+control/pmc12716432-35-25-20?v=OriGene
    Average 93 stars, based on 1 article reviews
    turbofectin 8 0 based transfection system - by Bioz Stars, 2026-08
    93/100 stars
    		  Buy from Supplier
    lipofectaminetm based sirna transfection reagent  (MedChemExpress)
    95
    MedChemExpress lipofectaminetm based sirna transfection reagent
    GLO1 knockdown downregulates PD-L1 and enhances CD8 + T cell function in vitro. A Representative RT-qPCR of GLO1 and PD-L1 expression in A375 and 786-O cells after transfection with control (si-NC) or GLO1-specific (si-GLO1) <t>siRNA.</t> GAPDH served as a loading control. B , C Quantification of mRNA B and PD-L1 C protein levels normalized to GAPDH ( n = 3, * p < 0.05, ** p < 0.01). D Representative flow cytometry plots showing the percentage of CD8 + T cells apoptosis after culture in conditioned medium from si-NC or si-GLO1 A375 cells. E , F Statistical summary of TNF-a ( E ) and IFN-γ production ( F ) in CD8 + T cells cultured in conditioned medium from si-NC or si-GLO1 treated A375 and 786-O cells ( n = 3, * p < 0.05, ** p < 0.01)
    Lipofectaminetm Based Sirna Transfection Reagent, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/transfection+control/pm41217230-27-29-33?v=MedChemExpress
    Average 95 stars, based on 1 article reviews
    lipofectaminetm based sirna transfection reagent - by Bioz Stars, 2026-08
    95/100 stars
    		  Buy from Supplier

    Image Search Results


    mAb B: effects of LC/HC promoter strength on titer, cell density, and viability post-transfection (72 hpt), and model profiling. (A) Viability (%), (B) viable cell density (VCD; cells/mL), and (C) titer (mg/L) for all LC/HC combinations. Promoter levels: 5, 40, and 100 RPU for both LC and HC. Bars show mean ± SD (n = 2). Statistical analysis was based on one-way ANOVA with Tukey's HSD; different letters indicate p < 0.05. (D) Transfection efficiency (% GFP+) of a control plasmid (pMAX-GFP) quantified by flow cytometry. (E) JMP profiler for least-squares models of titer, VCD, and viability versus LC/HC promoter strength. Left: predicted means with 95% Cls. Right: composite desirability (0-1) balancing high titer with acceptable VCD and viability. Red dashed lines mark targets/constraints.

    Journal: Frontiers in Bioengineering and Biotechnology

    Article Title: High-throughput optimization of antibody production in CHO cells by tuning heavy- and light-chain promoter strength

    doi: 10.3389/fbioe.2025.1747473

    Figure Lengend Snippet: mAb B: effects of LC/HC promoter strength on titer, cell density, and viability post-transfection (72 hpt), and model profiling. (A) Viability (%), (B) viable cell density (VCD; cells/mL), and (C) titer (mg/L) for all LC/HC combinations. Promoter levels: 5, 40, and 100 RPU for both LC and HC. Bars show mean ± SD (n = 2). Statistical analysis was based on one-way ANOVA with Tukey's HSD; different letters indicate p < 0.05. (D) Transfection efficiency (% GFP+) of a control plasmid (pMAX-GFP) quantified by flow cytometry. (E) JMP profiler for least-squares models of titer, VCD, and viability versus LC/HC promoter strength. Left: predicted means with 95% Cls. Right: composite desirability (0-1) balancing high titer with acceptable VCD and viability. Red dashed lines mark targets/constraints.

    Article Snippet: CHO-S cells (R80007, Life Technologies, Waltham, MA, United States) CD CHO medium (10743029, Gibco, Thermo Fisher Scientific, Waltham, MA, United States) L-Glutamine (25030081, Thermo Fisher Scientific, Waltham, MA, United States) Freestyle MAX Transfection Reagent (16447100, Thermo Fisher Scientific, Waltham, MA, United States) OptiPRO serum free medium (12309019, Thermo Fisher Scientific, Waltham, MA, United States) Transfection positive control expressing GFP (pMax-E2F1, 16007, Addgene, Watertown, MA, United States) Solution 18 (910-3018, ChemoMetec A/S, Allerød, Denmark) NC-Slide A8 (941-0002, ChemoMetec A/S, Allerød, Denmark)

    Techniques: Transfection, Control, Plasmid Preparation, Flow Cytometry

    mAb C: effects of LC/HC promoter strength on titer, cell density, and viability post-transfection (72 hpt), and model profiling. (A) Viability (6), (B) viable cell density (VCD; cells/mL), and (C) titer (mg/L) for all LC/HC combinations. Promoter levels: 5, 40, and 100 RPU for both LC and HC. Bars show mean = SD (n = 2). Statistical analysis was based on one-way ANOVA with Tukey’s HSD; different letters indicate p < 0.05. (D) JMP profiler for least-squares models of titer, VCD, and viability versus LC/HC promoter strength. Left: predicted means with 95% Cls. Right: composite desirability (0-1) balancing high titer with acceptable VCD and viability. Red dashed lines mark targets/constraints.

    Journal: Frontiers in Bioengineering and Biotechnology

    Article Title: High-throughput optimization of antibody production in CHO cells by tuning heavy- and light-chain promoter strength

    doi: 10.3389/fbioe.2025.1747473

    Figure Lengend Snippet: mAb C: effects of LC/HC promoter strength on titer, cell density, and viability post-transfection (72 hpt), and model profiling. (A) Viability (6), (B) viable cell density (VCD; cells/mL), and (C) titer (mg/L) for all LC/HC combinations. Promoter levels: 5, 40, and 100 RPU for both LC and HC. Bars show mean = SD (n = 2). Statistical analysis was based on one-way ANOVA with Tukey’s HSD; different letters indicate p < 0.05. (D) JMP profiler for least-squares models of titer, VCD, and viability versus LC/HC promoter strength. Left: predicted means with 95% Cls. Right: composite desirability (0-1) balancing high titer with acceptable VCD and viability. Red dashed lines mark targets/constraints.

    Article Snippet: CHO-S cells (R80007, Life Technologies, Waltham, MA, United States) CD CHO medium (10743029, Gibco, Thermo Fisher Scientific, Waltham, MA, United States) L-Glutamine (25030081, Thermo Fisher Scientific, Waltham, MA, United States) Freestyle MAX Transfection Reagent (16447100, Thermo Fisher Scientific, Waltham, MA, United States) OptiPRO serum free medium (12309019, Thermo Fisher Scientific, Waltham, MA, United States) Transfection positive control expressing GFP (pMax-E2F1, 16007, Addgene, Watertown, MA, United States) Solution 18 (910-3018, ChemoMetec A/S, Allerød, Denmark) NC-Slide A8 (941-0002, ChemoMetec A/S, Allerød, Denmark)

    Techniques: Transfection

    mAb E: effects of LC/HC promoter strength on titer, cell density, and viability post-transfection (72 hpt), and model profiling. (A) Viability (%), (B) viable cell density (VCD; cells/mL), and (C) titer (mg/L) for all LC/HC combinations. Promoter levels: 5, 40, and 100 RPU for both LC and HC. Bars show mean ± SD (n = 2). Statistical analysis was based on one-way ANOVA with Tukey’s HSD; different letters indicate p < 0.05. (D) JMP profiler for least- squares models of titer, VCD, and viability versus LC/HC promoter strength. Left: predicted means with 95% CIs. Right: composite desirability (0-1) balancing high titer with acceptable VCD and viability. Red dashed lines mark targets/constraints.

    Journal: Frontiers in Bioengineering and Biotechnology

    Article Title: High-throughput optimization of antibody production in CHO cells by tuning heavy- and light-chain promoter strength

    doi: 10.3389/fbioe.2025.1747473

    Figure Lengend Snippet: mAb E: effects of LC/HC promoter strength on titer, cell density, and viability post-transfection (72 hpt), and model profiling. (A) Viability (%), (B) viable cell density (VCD; cells/mL), and (C) titer (mg/L) for all LC/HC combinations. Promoter levels: 5, 40, and 100 RPU for both LC and HC. Bars show mean ± SD (n = 2). Statistical analysis was based on one-way ANOVA with Tukey’s HSD; different letters indicate p < 0.05. (D) JMP profiler for least- squares models of titer, VCD, and viability versus LC/HC promoter strength. Left: predicted means with 95% CIs. Right: composite desirability (0-1) balancing high titer with acceptable VCD and viability. Red dashed lines mark targets/constraints.

    Article Snippet: CHO-S cells (R80007, Life Technologies, Waltham, MA, United States) CD CHO medium (10743029, Gibco, Thermo Fisher Scientific, Waltham, MA, United States) L-Glutamine (25030081, Thermo Fisher Scientific, Waltham, MA, United States) Freestyle MAX Transfection Reagent (16447100, Thermo Fisher Scientific, Waltham, MA, United States) OptiPRO serum free medium (12309019, Thermo Fisher Scientific, Waltham, MA, United States) Transfection positive control expressing GFP (pMax-E2F1, 16007, Addgene, Watertown, MA, United States) Solution 18 (910-3018, ChemoMetec A/S, Allerød, Denmark) NC-Slide A8 (941-0002, ChemoMetec A/S, Allerød, Denmark)

    Techniques: Transfection

    GLO1 knockdown downregulates PD-L1 and enhances CD8 + T cell function in vitro. A Representative RT-qPCR of GLO1 and PD-L1 expression in A375 and 786-O cells after transfection with control (si-NC) or GLO1-specific (si-GLO1) siRNA. GAPDH served as a loading control. B , C Quantification of mRNA B and PD-L1 C protein levels normalized to GAPDH ( n = 3, * p < 0.05, ** p < 0.01). D Representative flow cytometry plots showing the percentage of CD8 + T cells apoptosis after culture in conditioned medium from si-NC or si-GLO1 A375 cells. E , F Statistical summary of TNF-a ( E ) and IFN-γ production ( F ) in CD8 + T cells cultured in conditioned medium from si-NC or si-GLO1 treated A375 and 786-O cells ( n = 3, * p < 0.05, ** p < 0.01)

    Journal: Discover Oncology

    Article Title: A comprehensive pan-cancer analysis of the prognostic role and immunotherapy efficacy evaluation of Glyoxalase 1

    doi: 10.1007/s12672-025-04109-3

    Figure Lengend Snippet: GLO1 knockdown downregulates PD-L1 and enhances CD8 + T cell function in vitro. A Representative RT-qPCR of GLO1 and PD-L1 expression in A375 and 786-O cells after transfection with control (si-NC) or GLO1-specific (si-GLO1) siRNA. GAPDH served as a loading control. B , C Quantification of mRNA B and PD-L1 C protein levels normalized to GAPDH ( n = 3, * p < 0.05, ** p < 0.01). D Representative flow cytometry plots showing the percentage of CD8 + T cells apoptosis after culture in conditioned medium from si-NC or si-GLO1 A375 cells. E , F Statistical summary of TNF-a ( E ) and IFN-γ production ( F ) in CD8 + T cells cultured in conditioned medium from si-NC or si-GLO1 treated A375 and 786-O cells ( n = 3, * p < 0.05, ** p < 0.01)

    Article Snippet: Cells were transfected with GLO1-specific small interfering RNA (siRNA) or non-targeting control siRNA (Santa Cruz Biotechnology) using Lipofectamine RNAiMAX Transfection Reagent (Invitrogen) according to the manufacturer’s instructions.

    Techniques: Knockdown, Cell Function Assay, In Vitro, Quantitative RT-PCR, Expressing, Transfection, Control, Flow Cytometry, Cell Culture